Enterprise Value
538M
Cash
1.073B
Avg Qtr Burn
-84.54M
Short % of Float
24.43%
Insider Ownership
1.87%
Institutional Own.
88.16%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BEAM-201 Details Blood cancer, Cancer, T-cell lymphoma, Acute lymphoblastic leukemia | Phase 1/2 Data readout | |
BEAM-101 Details Beta thalessemia, Sickle cell disease | Phase 1/2 Data readout |